Somatostatin analogues increase AIP expression in somatotropinomas, irrespective of Gsp mutations

Endocrine-Related Cancer

Volumn 20, Issue 5, 2013, Pages 753-766

  Jaffrain Rea, Marie Lise ^a,b   Rotondi, Sandra ^a   Turchi, Annarita ^a   Occhi, Gianluca ^c   Barlier, Anne ^d,e   Peverelli, Erika ^f   Rostomyan, Lilya ^g   Defilles, Céline ^d   Angelini, Mariolina ^a   Oliva, Maria Antonietta ^b   Ceccato, Filippo ^c   Maiorani, Orlando ^a   Dal, Adrian F ^g   Esposito, Vincenzo ^b,h   Buttarelli, Francesca ^h   Figarella Branger, Dominique ^d,i   Giangaspero, Felice ^b,j   Spada, Anna ^f   Scaroni, Carla ^c   Alesse, Edoardo ^a   Beckers, Albert ^g   more..

^a UNIVERSITY OF L'AQUILA   (Italy)

^b IRCCS NEUROMED   (Italy)

^c UNIVERSITY OF PADOVA   (Italy)

^d AIX MARSEILLE UNIVERSITY   (France)

^e AP HM Conception   (France)

^f UNIVERSITY OF MILAN   (Italy)

^g UNIVERSITY OF LIÈGE   (Belgium)

^h SAPIENZA UNIVERSITY OF ROME   (Italy)

ⁱ TIMONE HOSPITAL   (France)

^j SAPIENZA UNIVERSITY OF ROME   (Italy)

more..

Author keywords

Acromegaly; Aryl hydrocarbon receptor; Gsp mutations; Interacting protein; Pituitary adenoma; Somatostatin analogues

Indexed keywords

ANGIOPEPTIN; AROMATIC HYDROCARBON RECEPTOR; ARYL HYDROCARBON RECEPTOR INTERACTING PROTEIN; CARRIER PROTEINS AND BINDING PROTEINS; DOPAMINE RECEPTOR STIMULATING AGENT; GROWTH HORMONE; GUANINE NUCLEOTIDE BINDING PROTEIN; OCTREOTIDE; PROLACTIN; SOMATOMEDIN C; SOMATOSTATIN; UNCLASSIFIED DRUG;

ACROMEGALY; ADULT; AGED; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE MUTATION; GENETIC ANALYSIS; GROWTH HORMONE SECRETING ADENOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PREOPERATIVE TREATMENT; PROLACTIN BLOOD LEVEL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; TREATMENT DURATION; UPREGULATION;

EID: 84886400400     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-12-0322     Document Type: Article

References (45)

1. Angelini M, Turchi A, Tichomirowa M, Esposito V, Alesse E, Beckers A & Jaffrain-Rea ML. Somatotropinomas in patients with germline AIP mutations: absence of somatic mutations in the GNAS1 gene. 15th Congress of the European Neuroendocrine Association, Liège, 22-25 September 2010, Belgium (p 148)
2. Barlier A, Gunz G, Zamora AJ, Morange-Ramos I, Figarella-Branger D, Dufour H, Enjalbert A & Jaquet P 1998 Pronostic and therapeutic consequences of Gsa mutations in somatotroph adenomas. Journal of Clinical Endocrinology and Metabolism 83 1604-1610. (doi:10.1210/jc.83.5.1604)
3. Barlier A, Vanbellinghen JF, Daly AF, Silvy M, Jaffrain-Rea ML, Trouillas J, Tamagno G, Laure Cazabat L, Bours V, Brue T et al. 2007 Mutations in the aryl hydrocarbon receptor interacting protein gene are not highly prevalent among subjects with sporadic pituitary adenomas. Journal of Clinical Endocrinology and Metabolism 92 1952-1955. (doi:10.1210/jc.2006-2702)
4. Beckers A, Aaltonen LA, Daly AF & Karhu A 2013 Familial isolated pituitary adenomas (FIPA) and the pituitary adenoma predisposition due to mutations in the aryl hydrocarbon receptor interacting protein (AIP) gene. Endocrine Reviews 34 239-277. (doi:10.1210/er.2012-1013)
5. Beischlag TV, Luis Morales J, Hollingshead BD & Perdew GH 2008 The aryl hydrocarbon receptor complex and the control of gene expression. Critical Reviews in Eukaryotic Gene Expression 18 207-250. (doi:10.1615/ CritRevEukarGeneExpr.v18.i3.20)
6. Ben-Shlomo A & Melmed S 2010 Pituitary somatostatin receptor signaling. Trends in Endocrinology and Metabolism 21 123-133. (doi:10.1016/j.tem. 2009.12.003)
7. Bolger GB, Peden AH, Steele MR, MacKenzie C, McEwan DG, Wallace DA, Huston E, Baillie GS & Houslay MD 2003 Attenuation of the activity of the cAMP-specific phosphodiesterase PDE4A5 by interaction with the immunophilin XAP2. Journal of Biological Chemistry 278 33351-33363. (doi:10.1074/jbc. M303269200)
8. Cai W, Kramarova TV, Berg P, Korbonits M & Pongratz I 2011 The immunophilin-like protein XAP2 is a negative regulator of estrogen signaling through interaction with estrogen receptor a. PLoS ONE 6 e25201. (doi:10.1371/journal.pone.0025201)
9. Chahal HS, Trivellin G, Leontiou CA, Alband N, Fowkes RC, Tahir A, Igreja SC, Chapple JP, Jordan S, Lupp A et al. 2012 Somatostatin analogs modulate AIP in somatotroph adenomas: the role of the ZAC1 pathway. Journal of Clinical Endocrinology and Metabolism 97 E1411-E1420. (doi:10.1210/jc.2012-1111)
10. Daly AF, Vanbellinghen JF, Khoo SK, Jaffrain-Rea ML, Naves LA, Guitelman MA, Murat A, Emy P, Gimenez-Roqueplo AP, Tamburrano G et al. 2007 Aryl hydrocarbon receptor-interacting protein gene mutations in familial isolated pituitary adenomas: analysis in 73 families. Journal of Clinical Endocrinology and Metabolism 92 1891-1896. (doi:10.1210/jc.2006-2513)
11. Daly AF, Tichomirowa MA, Petrossians P, Heliövaara E, Jaffrain-Rea ML, Barlier A, Naves LA, Ebeling T, Karhu A, Raappana A et al. 2010 Clinical characteristics and therapeutic responses in patients with germ-line AIP mutations and pituitary adenomas: an international collaborative study. Journal of Clinical Endocrinology and Metabolism 95 E373-E383. (doi:10.1210/jc.2009- 2556)
12. Dietrich C & Kaina B 2010 The aryl hydrocarbon receptor (AhR) in the regulation of cell-cell contact and tumor growth. Carcinogenesis 31 1319-1328. (doi:10.1093/carcin/bgq028)
13. Durán-Prado M, Saveanu A, Luque RM, Gahete MD, Gracia-Navarro F, Jaquet P, Dufour H, Malagón MM, Culler MD, Barlier A et al. 2010 A potential inhibitory role for the new truncated variant of somatostatin receptor 5, sst5TMD4, in pituitary adenomas poorly responsive to somatostatin analogs. Journal of Clinical Endocrinology and Metabolism 95 2497-2502. (doi:10.1210/jc.2009-2247)
14. Durán-Prado M, Gahete MD, Delgado-Niebla E, Martínez- Fuentes AJ, Vázquez-Martínez R, García-Navarro S, Gracia-Navarro F, Malagon MM, Luque RM & Castaño JP 2012 Truncated variants of pig somatostatin receptor subtype 5 (sst5) act as dominant-negative modulators for sst2- mediated signaling. American Journal of Physiology. Endocrinology and Metabolism 303 E1325-E1334. (doi:10.1152/ajpendo.00445.2012)
15. Ferrante E, Pellegrini C, Bondioni S, Peverelli E, Locatelli M, Gelmini P, Lucani P, Peri A, Mantovani G, Bosari S et al. 2006 Octreotide promotes apoptosis in human somatotroph tumor cells by activating somatostatin receptor type 2. Endocrine-Related Cancer 13 955-962. (doi:10.1677/erc.1.01191)
16. Formosa R, Xuereb-Anastasi A & Vassallo J 2013 AIP regulates cAMP signalling and GH secretion in GH3 cells. Endocrine-Related Cancer 20 495-505. (doi:10.1530/ERC-13-0043)
17. Harper PA, Riddick DS & Okey AB 2006 Regulating the key regulator: factors that control levels and activity of the aryl hydrocarbon receptor. Biochemical Pharmacology 72 267-279. (doi:10.1016/j.bcp.2006.01.007)
18. Heliövaara E, Raitila A, Launonen V, Paetau A, Arola J, Lehtonen H, Sane T, Weil RJ, Vierimaa O, Salmela P et al. 2009 The expression of AIP-related molecules in elucidation of cellular pathways in pituitary adenomas. American Journal of Pathology 175 2501-2507. (doi:10.2353/ajpath. 2009.081131)
19. Hubina E, Nanzer AM, Hanson MR, Ciccarelli E, Losa M, Gaia D, Papotti M, Terreni MR, Khalaf S, Jordan S et al. 2006 Somatostatin analogues stimulate p27 expression and inhibit the MAP kinase pathway in pituitary tumours. European Journal of Endocrinology 155 371-379. (doi:10.1530/eje.1.02213)
20. Iwata T,Yamada S,Mizusawa N,GolamHM,Sano T&YoshimotoK2007 The aryl hydrocarbon receptor-interacting protein gene is rarely mutated in sporadic GH-secreting adenomas. Clinical Endocrinology 66 499-502. (doi:10.1111/j.1365- 2265.2007.02758.x)
21. Jaffrain-Rea ML, Di Stefano D, Minniti G, Esposito V, Bultrini A, Ferretti E, Santoro A, Faticanti Scucchi L, Gulino A & Cantore G 2002 A critical reappraisal of MIB-1 labelling index significance in a large series of pituitary tumours: secreting versus non-secreting adenomas. Endocrine- Related Cancer 9 103-113. (doi:10.1677/erc.0.0090103)
22. Jaffrain-Rea ML, Angelini M, Gargano D, Tichomirowa MA, Daly AF, Vanbellinghen JF, D'Innocenzo E, Barlier A, Giangaspero F, Esposito V et al. 2009 Expression of aryl hydrocarbon receptor (AHR) and AHRinteracting protein in pituitary adenomas: pathological and clinical implications. Endocrine-Related Cancer 16 1029-1043. (doi:10.1677/ ERC-09-0094)
23. Jaffrain-Rea ML, Angelini M, Tichomirowa MA,Theodoropoulou M, Daly AF, Barlier A, Naves LA, Fajardo C, Zacharieva S,RohmerV et al. 2010. Factors associated with AIP expression in somatotropinomas and the possible influence of somatostatin analogues. 15th Congress of the European Neuroendocrine Association, Liège, 22-25 September 2010, Belgium (p 78)
24. Kasuki Jomori de Pinho L, Vieira Neto L, Armondi Wildemberg LE, Gasparetto EL, Marcondes J, de Almeida Nunes B, Takiya CM & Gadelha MR 2011 Low aryl hydrocarbon receptor-interacting protein expression is a bettermarker of invasiveness in somatotropinomas than Ki-67 and p53. Neuroendocrinology 94 39-48. (doi:10.1159/000322787)
25. Kasuki L, Vieira Neto L, Wildemberg LE, Colli LM, de Castro M, Takiya CM & Gadelha MR 2012 AIP expression in sporadic somatotropinomas is a predictor of the response to octreotide LAR therapy independent of SSTR2 expression. Endocrine-Related Cancer 19 L25-L29. (doi:10.1530/ ERC-12-0020)
26. Lania A, Persani L, Ballarè E, Mantovani S, Losa M & Spada A 1998 Constitutively active Gsa is associated with an increased phosphodiesterase activity in human growth hormone-secreting adenomas. Journal of Clinical Endocrinology and Metabolism 83 1624-1628. (doi:10.1210/jc.83.5.1624)
27. Lania AG, Mantovani G & Spada A 2003 Genetics of pituitary tumours: focus on G-protein mutations. Experimental Biology and Medicine 228 1004-1017.
28. Lania AG, Mantovani G, Ferrero S, Pellegrini C, Bondioni S, Peverelli E, Braidotti P, Locatelli M, Zavanone ML, Ferrante E et al. 2004 Proliferation of transformed somatotroph cells related to low or absent expression of protein kinase A regulatory subunit 1A protein. Cancer Research 64 9193-9198. (doi:10.1158/0008-5472.CAN-04-1847)
29. Leontiou CA, Gueorguiev M, van der Spuy J, Quinton R, Lolli F, Hassan S, Chahal HS, Igreja SC, Jordan S, Rowe J et al. 2008 The role of the aryl hydrocarbon receptor-interacting protein gene in familial and sporadic pituitary adenomas. Journal of Clinical Endocrinology and Metabolism 93 2390-2401. (doi:10.1210/jc.2007-2611)
30. Losa M, Ciccarelli E, Mortini P, Barzaghi R, Gaia D, Faccani G, Papotti M, Mangili F, Terreni MR, Camanni F et al. 2001 Effects of octreotide treatment on the proliferation and apoptotic index of GH-secreting pituitary adenomas. Journal of Clinical Endocrinology and Metabolism 86 5194-5200. (doi:10.1210/jc.86.11.5194)
31. Marlowe JL & Puga A 2005 Aryl hydrocarbon receptor, cell cycle regulation, toxicity, and tumorigenesis. Journal of Cellular Biochemistry 96 1174-1184. (doi:10.1002/jcb.20656)
32. Matthews J & Gustafsson JA 2006 Estrogen receptor and aryl hydrocarbon receptor signaling pathways. Nuclear Receptor Signaling 4 e016. (doi:10.162/nrs.04016)
33. Nguyen LP & Bradfield CA 2008 The search for endogenous activators of the aryl hydrocarbon receptor. Chemical Research in Toxicology 21 102-116. (doi:10.1021/tx7001965)
34. Oesch-Bartlomowicz B, Huelster A,Wiss O, Antoniou-Lipfert P, Dietrich C, Arand M, Weiss C, Bockamp E & Oesch F 2005 Aryl hydrocarbon receptor activation by cAMP vs. dioxin: divergent signaling pathways. PNAS 102 9218-9223. (doi:10.1073/pnas.0503488102)
35. Occhi G, Jaffrain-Rea ML, Trivellin G, Albiger N, Ceccato F, De Menis E, Angelini M, Ferasin S, Beckers A, Mantero F et al 2010 The R304X mutation of the aryl hydrocarbon receptor interacting protein gene in familial isolated pituitary adenomas: mutational hot-spot or founder effect? Journal of Endocrinological Investigation 33 800-805. (doi:10.3275/6956)
36. Occhi G, Losa M, Albiger N, Trivellin G, Regazzo D, Scanarini M, Monteserin-Garcia JL, Fröhlich B, Ferasin S, Terreni MR et al. 2011 The glucose-dependent insulinotropic polypeptide receptor is overexpressed amongst GNAS1 mutation-negative somatotropinomas and drives growth hormone (GH) -promoter activity in GH3 cells. Journal of Neuroendocrinology 23 641-649. (doi:10.1111/j.1365-2826. 2011.02155.x)
37. de Oliveira SK, Hoffmeister M, Gambaryan S,Müller-Esterl W, Guimaraes JA & Smolenski AP 2007 Phosphodiesterase 2A forms a complex with the co-chaperone XAP2 and regulates nuclear translocation of the aryl hydrocarbon receptor. Journal of Biological Chemistry 282 13656-13663. (doi:10.1074/jbc.M610942200)
38. Pertuit M, Barlier A, Enjalbert A & Gérard C 2009 Signalling pathway alterations in pituitary adenomas: involvement of Gsa, cAMP and mitogen-activated protein kinases. Neuroendocrinology 21 869-877. (doi:10.1111/j.1365-2826.2009.01910.x)
39. Petrulis JR & Perdrew GH 2002 The role of chaperone proteins in the aryl hydrocarbon receptor core complex. Chemico-Biological Interactions 141 25-40. (doi:10.1016/S0009-2797(02) 00064-9)
40. Raitila A, Lehtonen HJ, Arola J, Heliövaara E, Ahlsten M, Georgitsi M, Jalanko A, Paetau A, Aaltonen LA & Karhu A 2010 Mice with inactivation of aryl hydrocarbon receptor-interacting protein (AIP) display complete penetrance of pituitary adenomas with aberrant ARNT expression. American Journal of Pathology 177 1969-1976. (doi:10.2353/ajpath.2010.100138)
41. Theodoropoulou M, Zhang J, Laupheimer S, Paez-Pereda M, Erneux C, Florio T, Pagotto U & Stalla GK 2006 Octreotide, a somatostatin analogue, mediates its antiproliferative action in pituitary tumor cells by altering phosphatidylinositol 3-kinase signaling and inducing Zac1 expression. Cancer Research 66 1576-1582. (doi:10.1158/0008-5472. CAN-05-1189)
42. Theodoropoulou M, Tichomirowa MA, Sievers C, Yassouridis A, Arzberger T, Hougrand O, Deprez M, Daly AF, Petrossians P, Pagotto U et al. 2009 Tumor ZAC1 expression is associated with the response to somatostatin analog therapy in patients with acromegaly. International Journal of Cancer 125 2122-2126. (doi:10.1002/ijc.24602)
43. Trivellin G, Butz H, Delhove J, Igreja S, Chahal HS, Zivkovic V, McKay T, Pató cs A, Grossman AB & Korbonits M 2012 MicroRNA miR-107 is overexpressed in pituitary adenomas and in vitro inhibits the expression of aryl hydrocarbon receptor-interacting protein (AIP) American Journal of Physiology. Endocrinology and Metabolism 303 E708-E719. (doi:10.1152/ajpendo.00546.2011)
44. Vierimaa O, Georgitsi M, Lehtonen R, Vahteristo P, Kokko A, Raitila A, Tuppurainen K, Ebeling TM, Salmela PI, Paschke R et al. 2006 Pituitary adenoma predisposition caused by germline mutations in the AIP gene. Science 312 1228-1230. (doi:10.1126/science. 1126100)
45. Zatelli MC, Piccin D, Tagliati F, Bottoni A, Ambrosio MR, Margutti A, Scanarini M, Bondanelli M, Culler MD & degli Uberti EC 2005 Dopamine receptor subtype 2 and somatostatin receptor subtype 5 expression influences somatostatin analogs effects on human somatotroph pituitary adenomas in vitro. Journal of Molecular Endocrinology 35 333-341. (doi:10.1677/jme.1.01876)